PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Journal of Inflammation Research2 citationsOpen Access

Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory Diseases

ZHZelin HeNCNuoshi ChenYZYuan Zhang

Key Points

  • This review aims to explore the role of impaired macrophage efferocytosis in the pathogenesis of immune-mediated inflammatory diseases.
  • Reviewed mechanistic studies of efferocytosis dysfunction in immune-mediated inflammatory diseases.
  • Analyzed the role of TAM receptors and bridging molecules in macrophage function.
  • Integrated insights into immunometabolic and epigenetic reprogramming related to chronic inflammation.
  • Discussed therapeutic strategies targeting efferocytosis pathways.
  • Defective efferocytosis is implicated in the progression of various immune-mediated inflammatory diseases.
  • Dysregulated TAM receptors and intracellular signaling pathways contribute to efferocytosis dysfunction.
  • Targeting efferocytosis pathways may offer new therapeutic avenues for immune-mediated inflammatory diseases.

Abstract

Abstract: Efferocytosis, the specialized phagocytic clearance of apoptotic cells, is a fundamental mechanism for maintaining tissue homeostasis and immune tolerance. Among professional phagocytes, macrophages play a central role due to their high plasticity and tissue-resident properties. By recognizing and engulfing apoptotic cells through a repertoire of receptors and bridging molecules, macrophages prevent secondary necrosis and inflammation and actively shape the local immune microenvironment via metabolic and epigenetic reprogramming. Defective efferocytosis has been increasingly implicated in the pathogenesis of immune-mediated inflammatory diseases (IMIDs), including systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, inflammatory bowel disease, psoriasis, atopic dermatitis, and autoimmune liver diseases. Impairments in efferocytosis trigger persistent inflammation, autoantigen exposure, and tissue damage, thereby fueling chronic disease progression. Recent mechanistic studies highlight the dysregulation of TAM receptors, bridging molecules, and intracellular signaling pathways as critical determinants of efferocytosis dysfunction in IMIDs. In this review, we propose defective macrophage efferocytosis as a shared pathogenic mechanism across diverse IMIDs and integrate emerging evidence linking efferocytosis to immunometabolic and epigenetic rewiring in chronic inflammation. We further discuss therapeutic strategies targeting efferocytosis pathways and highlight key translational challenges and opportunities. By positioning efferocytosis as a central pathogenic node and a readily targetable mechanism across the spectrum of IMIDs, this review offers a conceptual framework that links fundamental mechanistic insights with clinical translation, thereby laying the groundwork for precision immunomodulatory strategies that aim to restore immune homeostasis rather than merely suppress inflammation. Keywords: macrophage efferocytosis, immune-mediated inflammatory diseases, TAM receptors, apoptotic cell clearance, inflammation resolution

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

He et al. (2026) studied this question.

synapsesocial.com/papers/69d896046c1944d70ce072b7https://doi.org/10.2147/jir.s582297
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset2024 · 77 citations
  2. 2Atopic dermatitis2020 · 1,831 citations
  3. 3Lupus-like autoimmune disease caused by a lack of Xkr8, a caspase-dependent phospholipid scramblase2018 · 62 citations
  4. 4Psoriasis2015 · 2,547 citations
  5. 5Clinically confirmed DEL-1 as a myokine attenuates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes via AMPK/HO-1- pathway2020 · 29 citations